Condition: HER2-positive Gastric Cancer · Metastatic Gastric Cancer · Unresectable Gastric Carcinoma · Sponsor: Qilu Hospital of Shandong University
This is a Phase II, randomized, multicenter, open-label clinical trial designed to compare Disitamab Vedotin plus Sintilimab and S-1 with Trastuzumab plus chemotherapy ± Sintilimab for first-line treatment of HER2-Positive advanced gastric or gastroesophageal junction adenocarcinoma.
This description comes directly from the study's public registry record.
Lian Liu, MD · 0531-82169851 · tounao@126.com
Song Li, MD · 0531-82169851
Always discuss trial participation with your own doctor first.
| The First Affiliated Hospital of Zhengzhou University | Zhengzhou, Henan, China | Recruiting |
| Binzhou Medical University Hospital | Binzhou, Shandong, China | Not Yet Recruiting |
| Shengli Oilfield Central Hospital | Dongying, Shandong, China | Recruiting |
| Shandong Provincial Hospital Affiliated to Shandong First Medical University | Jinan, Shandong, China | Recruiting |
| Shandong Provincial Third Hospital | Jinan, Shandong, China | Recruiting |
| Shandong Univerisity Qilu Hospital | Jinan, Shandong, China | Recruiting |
| Jinan Third People's Hospital | Jinan, Shandong, China | Recruiting |
| Affiliated Hospital of Jining Medical College | Jining, Shandong, China | Recruiting |
| Liaocheng People's Hospital | Liaocheng, Shandong, China | Recruiting |
| Linyi Cancer Hospital | Linyi, Shandong, China | Recruiting |
| Qilu Hospital of Shandong University(Qingdao) | Qingdao, Shandong, China | Recruiting |
| The Affiliated Hospital of Qingdao University | Qingdao, Shandong, China | Not Yet Recruiting |
+ 8 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06730373